EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?

Adhya Mehta, Roger S Blumenthal, Ty J Gluckman, David I Feldman, Payal Kohli

US Cardiology Review · 21.03.2025 · 19

DOI: 10.15420/usc.2024.25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift US Cardiology Review, online erschienen am 21.03.2025. Verfasst von Adhya Mehta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Albert Einstein College of Medicine/Jacobi Medical Center Bronx, NY. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation and dyslipidemia are central to the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). While lipid-lowering therapies are the cornerstone of ASCVD prevention and treatment, there are other emerging targets, including inflammation (which has been dubbed the ‘residual inflammatory risk’), that can be addressed after LDL cholesterol thresholds have been reached. Research over the past 20 years has identified C-reactive protein (CRP) as a key marker of inflammation with atherosclerosis. The association of more sensitive measures of CRP (high-sensitivity C-reactive protein [hsCRP]) with ASCVD risk in epidemiological studies has also led to its incorporation as a risk enhancer in primary prevention guidelines and its incorporation into risk stratification tools. While there are no formal recommendations related to measurement of hsCRP in secondary prevention, consideration should be given to an individualized approach that addresses inflammatory risk in those with major adverse cardiovascular events, despite maximal lipid-lowering therapy and well-controlled LDL cholesterol levels. The aim of this review is to discuss the role of inflammation in ASCVD, the use of hsCRP as a tool to assess residual inflammatory risk to target upstream pathways such as glucose intolerance and obesity, and to consider use of additional anti-inflammatory medications for ASCVD risk reduction. The authors provide clinical context around when to measure hsCRP in clinical practice and how to address residual inflammatory risk in ASCVD.

Schlagwörter

Stichwörter der Autor:innen

Atherosclerotic cardiovascular diseasehigh-sensitivity C-reactive proteininflammationresidual cholesterol riskresidual inflammatory risk

Autor:innen und Institutionen

  • Department of Internal Medicine, Albert Einstein College of Medicine/Jacobi Medical Center Bronx, NY.
  • Division of Cardiology, Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine Baltimore, MD.
  • Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence Joseph Health System Portland, OR.
  • Massachusetts General Hospital, Harvard Medical School Boston, MA.
  • Department of Cardiology, Johns Hopkins University Baltimore, MD.

Zitieren

APA

Mehta, A., Blumenthal, R. S., Gluckman, T. J., Feldman, D. I., & Kohli, P. (2025). High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?. US Cardiology Review, 19. https://doi.org/10.15420/usc.2024.25

Vancouver

Mehta A, Blumenthal RS, Gluckman TJ, Feldman DI, Kohli P. High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?. US Cardiology Review. 2025;19. doi:10.15420/usc.2024.25

BibTeX
@article{Mehta2025,
  author = {Mehta, Adhya and Blumenthal, Roger S and Gluckman, Ty J and Feldman, David I and Kohli, Payal},
  title = {High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?},
  journal = {US Cardiology Review},
  year = {2025},
  volume = {19},
  doi = {10.15420/usc.2024.25}
}
Kostenlos starten →